CMB-401

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCMB-401

Drug Alias NameCDP-671CMB-401

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionDNA inhibitorsAnti-MUC1

TargetsMucin-1DNA

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCelltech

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCelltech

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian Neoplasms

Other Information

ATC CodeN/A